Position in NAMS
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$5,140,806
-$493,042 QoQ
Shares Held
160,600
0.0% QoQ
Ownership
0.137%
of shares outstanding
% of Portfolio
2.22%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026DCF Advisers, LLC holds $55,922,160 across 20 Biotechnology names. NAMS ranks #4 (9.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
14,650 | $10,698,162 | |
| 2 | CRVS |
Corvus Pharmaceuticals, Inc.
|
637,500 | $9,326,625 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,250 | $7,146,920 | |
| 4 | NAMS |
NewAmsterdam Pharma Co N.V.
This page
|
160,600 | $5,140,806 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
56,000 | $4,205,040 | |
| 6 | INCY |
Incyte Corp
|
41,500 | $3,905,980 | |
| 7 | HELP |
Cybin Inc.
|
691,988 | $3,321,542 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,000 | $3,125,780 |
All Filings in NAMS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,140,806 | 160,600 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $5,633,848 | 160,600 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $4,984,110 | 175,250 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $3,123,975 | 172,500 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $3,531,075 | 172,500 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $2,297,580 | 89,400 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $564,400 | 34,000 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||